This co-expression pattern indicates that DLL3 is transcriptionally regulated by ASCL1, thereby establishing a mechanistic rationale for subtype-oriented precision therapies targeting the ASCL1–DLL3 signaling axis in SCLC. Here, DLL3 is linked to small cell lung carcinoma.